|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000277443 |
Summary for MARCKS |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000277443 | Gene symbol | MARCKS |
| Gene name | myristoylated alanine rich protein kinase C substrate | |
| HGNC | 6759 | |
| Entrez ID | 4082 | |
| Gene type | protein_coding | |
| Synonyms | MARCKS|PKCSL|80K-L | |
| UniProtAcc | P29966 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for MARCKS |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MARCKS | 1.14e+04 | 1.30e+00 | 9.11e-02 | 1.43e+01 | 3.56e-46 | 6.04e-45 | KIRC |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for MARCKS |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for MARCKS |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg12850036 | chr6:113856150 | CGI:chr6:113858558-113860511 | promoter | 2.09e-01 | 5.41e-02 | 9.62e+00 | 6.48e-22 | 4.13e-21 | 1.55e-01 |
| BRCA | cg18668813 | chr6:113856162 | CGI:chr6:113858558-113860511 | promoter | 2.77e-01 | 6.26e-02 | 1.08e+01 | 3.77e-27 | 3.97e-26 | 2.14e-01 |
| BRCA | cg21116267 | chr6:113856320 | CGI:chr6:113858558-113860511 | promoter | 2.21e-01 | 5.66e-02 | 9.90e+00 | 4.31e-23 | 3.06e-22 | 1.64e-01 |
| BRCA | cg07271302 | chr6:113856356 | CGI:chr6:113858558-113860511 | promoter | 3.01e-01 | 8.46e-02 | 1.06e+01 | 1.86e-26 | 1.82e-25 | 2.16e-01 |
| LUAD | cg12850036 | chr6:113856150 | CGI:chr6:113858558-113860511 | promoter | 1.94e-01 | 5.51e-02 | 2.66e+00 | 7.88e-03 | 1.33e-02 | 1.39e-01 |
| LUAD | cg18668813 | chr6:113856162 | CGI:chr6:113858558-113860511 | promoter | 2.60e-01 | 1.00e-01 | 1.98e+00 | 4.72e-02 | 4.78e-02 | 1.60e-01 |
| LUAD | cg21116267 | chr6:113856320 | CGI:chr6:113858558-113860511 | promoter | 2.22e-01 | 7.24e-02 | 2.26e+00 | 2.35e-02 | 2.90e-02 | 1.49e-01 |
Top |
Exon skipping events with PSI in TCGA for MARCKS |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for MARCKS |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for MARCKS |
| TFs related to MARCKS. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BLCA | KLF1 | MARCKS | 4.58e+00 | 9.94e-01 | 2.64e+00 | 1.94e-04 | Male-biased |
| BLCA | KLF11 | MARCKS | 4.49e+00 | 9.93e-01 | 2.65e+00 | 2.86e-04 | Male-biased |
| BLCA | KLF14 | MARCKS | 4.39e+00 | 9.89e-01 | 3.24e+00 | 3.00e-03 | Male-biased |
| BLCA | KLF15 | MARCKS | 4.32e+00 | 9.90e-01 | 2.86e+00 | 1.08e-03 | Male-biased |
| BLCA | KLF16 | MARCKS | 4.27e+00 | 9.89e-01 | 2.83e+00 | 1.15e-03 | Male-biased |
| BLCA | KLF17 | MARCKS | 3.93e+00 | 9.80e-01 | 2.44e+00 | 9.36e-04 | Male-biased |
| BLCA | KLF2 | MARCKS | 4.26e+00 | 9.89e-01 | 2.89e+00 | 1.39e-03 | Male-biased |
| BLCA | KLF5 | MARCKS | 4.55e+00 | 9.94e-01 | 2.65e+00 | 2.22e-04 | Male-biased |
| BLCA | KLF7 | MARCKS | 4.88e+00 | 9.96e-01 | 2.80e+00 | 1.16e-04 | Male-biased |
| BLCA | KLF9 | MARCKS | 4.68e+00 | 9.95e-01 | 2.82e+00 | 2.63e-04 | Male-biased |
| BLCA | PATZ1 | MARCKS | 3.99e+00 | 9.83e-01 | 2.23e+00 | 3.76e-04 | Male-biased |
| BLCA | SP1 | MARCKS | 4.39e+00 | 9.91e-01 | 2.96e+00 | 1.18e-03 | Male-biased |
| BLCA | SP2 | MARCKS | 4.31e+00 | 9.89e-01 | 3.02e+00 | 1.89e-03 | Male-biased |
| BLCA | SP3 | MARCKS | 4.52e+00 | 9.93e-01 | 2.93e+00 | 7.11e-04 | Male-biased |
| BLCA | SP4 | MARCKS | 4.34e+00 | 9.89e-01 | 3.13e+00 | 2.39e-03 | Male-biased |
| BLCA | SP8 | MARCKS | 4.53e+00 | 9.93e-01 | 3.05e+00 | 9.99e-04 | Male-biased |
| BLCA | SP9 | MARCKS | 4.35e+00 | 9.89e-01 | 3.13e+00 | 2.37e-03 | Male-biased |
| BLCA | VEZF1 | MARCKS | 4.09e+00 | 9.84e-01 | 2.88e+00 | 2.42e-03 | Male-biased |
| BLCA | WT1 | MARCKS | 4.31e+00 | 9.90e-01 | 2.82e+00 | 9.61e-04 | Male-biased |
| BLCA | ZBTB17 | MARCKS | 4.07e+00 | 9.81e-01 | 3.05e+00 | 4.45e-03 | Male-biased |
| BLCA | ZBTB26 | MARCKS | 4.10e+00 | 9.84e-01 | 2.93e+00 | 2.78e-03 | Male-biased |
| BLCA | ZNF132 | MARCKS | 4.05e+00 | 9.84e-01 | 2.58e+00 | 9.93e-04 | Male-biased |
| BLCA | ZNF180 | MARCKS | 4.61e+00 | 9.94e-01 | 2.96e+00 | 5.69e-04 | Male-biased |
| BLCA | ZNF267 | MARCKS | 4.59e+00 | 9.94e-01 | 2.75e+00 | 2.88e-04 | Male-biased |
| BLCA | ZNF281 | MARCKS | 4.11e+00 | 9.86e-01 | 2.39e+00 | 4.36e-04 | Male-biased |
| BLCA | ZNF311 | MARCKS | 4.72e+00 | 9.95e-01 | 2.67e+00 | 1.31e-04 | Male-biased |
| BLCA | ZNF37A | MARCKS | 3.94e+00 | 9.81e-01 | 2.41e+00 | 8.12e-04 | Male-biased |
| BLCA | ZNF398 | MARCKS | 3.94e+00 | 9.81e-01 | 2.39e+00 | 7.60e-04 | Male-biased |
| BLCA | ZNF432 | MARCKS | 4.12e+00 | 9.84e-01 | 2.97e+00 | 2.84e-03 | Male-biased |
| BLCA | ZNF441 | MARCKS | 4.67e+00 | 9.94e-01 | 3.15e+00 | 8.92e-04 | Male-biased |
| BLCA | ZNF444 | MARCKS | 4.15e+00 | 9.87e-01 | 2.52e+00 | 5.88e-04 | Male-biased |
| BLCA | ZNF467 | MARCKS | 4.14e+00 | 9.85e-01 | 2.94e+00 | 2.46e-03 | Male-biased |
| BLCA | ZNF484 | MARCKS | 4.03e+00 | 9.84e-01 | 2.52e+00 | 8.75e-04 | Male-biased |
| BLCA | ZNF529 | MARCKS | 4.50e+00 | 9.93e-01 | 2.71e+00 | 3.43e-04 | Male-biased |
| BLCA | ZNF682 | MARCKS | 4.38e+00 | 9.92e-01 | 2.44e+00 | 1.89e-04 | Male-biased |
| BLCA | ZNF880 | MARCKS | 4.06e+00 | 9.83e-01 | 2.77e+00 | 1.84e-03 | Male-biased |
| BLCA | ZSCAN22 | MARCKS | 4.34e+00 | 9.91e-01 | 2.52e+00 | 2.98e-04 | Male-biased |
| CHOL | FOXF1 | MARCKS | 4.43e+00 | 9.84e-01 | 3.47e+00 | 1.06e-02 | Male-biased |
| CHOL | FOXR2 | MARCKS | 4.15e+00 | 9.89e-01 | 2.86e+00 | 2.61e-03 | Male-biased |
| CHOL | LHX3 | MARCKS | 4.32e+00 | 9.82e-01 | 3.38e+00 | 1.15e-02 | Male-biased |
| CHOL | NKX6-1 | MARCKS | 4.01e+00 | 9.82e-01 | 2.94e+00 | 6.46e-03 | Male-biased |
| CHOL | SOX2 | MARCKS | 4.58e+00 | 9.85e-01 | 3.61e+00 | 1.02e-02 | Male-biased |
| CHOL | SOX21 | MARCKS | 4.78e+00 | 9.85e-01 | 3.84e+00 | 1.19e-02 | Male-biased |
| CHOL | SOX4 | MARCKS | 4.72e+00 | 9.88e-01 | 3.71e+00 | 8.65e-03 | Male-biased |
| CHOL | SOX7 | MARCKS | 4.67e+00 | 9.88e-01 | 3.62e+00 | 7.48e-03 | Male-biased |
| CHOL | SRY | MARCKS | 4.93e+00 | 9.89e-01 | 3.91e+00 | 8.57e-03 | Male-biased |
| CHOL | ZNF418 | MARCKS | 3.93e+00 | 9.86e-01 | 2.38e+00 | 8.48e-04 | Male-biased |
| CHOL | ZNF570 | MARCKS | 3.98e+00 | 9.82e-01 | 2.88e+00 | 5.65e-03 | Male-biased |
| CHOL | ZNF584 | MARCKS | 4.47e+00 | 9.83e-01 | 3.53e+00 | 1.13e-02 | Male-biased |
| DLBC | FOXF1 | MARCKS | 3.47e+00 | 7.51e-03 | 4.44e+00 | 9.85e-01 | Female-biased |
| DLBC | FOXR2 | MARCKS | 2.58e+00 | 7.53e-04 | 4.21e+00 | 9.89e-01 | Female-biased |
| DLBC | LHX3 | MARCKS | 3.50e+00 | 1.09e-02 | 4.37e+00 | 9.81e-01 | Female-biased |
| DLBC | NKX6-1 | MARCKS | 2.76e+00 | 2.36e-03 | 4.04e+00 | 9.84e-01 | Female-biased |
| DLBC | SOX2 | MARCKS | 3.68e+00 | 9.34e-03 | 4.60e+00 | 9.85e-01 | Female-biased |
| DLBC | SOX4 | MARCKS | 3.71e+00 | 1.18e-02 | 4.56e+00 | 9.82e-01 | Female-biased |
| DLBC | SOX7 | MARCKS | 3.60e+00 | 8.78e-03 | 4.53e+00 | 9.85e-01 | Female-biased |
| DLBC | SRY | MARCKS | 4.00e+00 | 9.95e-03 | 4.90e+00 | 9.87e-01 | Female-biased |
| DLBC | ZNF418 | MARCKS | 2.05e+00 | 3.58e-04 | 3.91e+00 | 9.83e-01 | Female-biased |
| DLBC | ZNF584 | MARCKS | 3.28e+00 | 4.38e-03 | 4.40e+00 | 9.88e-01 | Female-biased |
| GBM | ZNF311 | MARCKS | 4.29e+00 | 9.80e-01 | 3.18e+00 | 9.45e-03 | Male-biased |
| LAML | LHX3 | MARCKS | 3.91e+00 | 1.24e-02 | 4.76e+00 | 9.82e-01 | Female-biased |
| LAML | SOX2 | MARCKS | 4.26e+00 | 1.19e-02 | 5.11e+00 | 9.85e-01 | Female-biased |
| LAML | SOX21 | MARCKS | 4.44e+00 | 1.54e-02 | 5.23e+00 | 9.82e-01 | Female-biased |
| LAML | SRY | MARCKS | 4.62e+00 | 1.39e-02 | 5.43e+00 | 9.84e-01 | Female-biased |
| PCPG | SOX13 | MARCKS | 3.79e+00 | 1.16e-02 | 4.56e+00 | 9.83e-01 | Female-biased |
| PCPG | SOX17 | MARCKS | 3.51e+00 | 9.64e-03 | 4.32e+00 | 9.82e-01 | Female-biased |
| PCPG | SOX2 | MARCKS | 3.50e+00 | 8.56e-03 | 4.34e+00 | 9.83e-01 | Female-biased |
| PCPG | SRY | MARCKS | 3.73e+00 | 7.09e-03 | 4.62e+00 | 9.88e-01 | Female-biased |
| MARCKS related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for MARCKS |
| RBPs related to ES in MARCKS. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| MARCKS related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000277443 | AC022035.1,hsa-mir-216a,MARCKS | Male-specific ceRNA | TCGA-KIRC |
| ENSG00000277443 | AC010186.3,hsa-mir-216a,MARCKS | Male-specific ceRNA | TCGA-KIRC |
| ENSG00000277443 | AC015712.2,hsa-mir-216a,MARCKS | Male-specific ceRNA | TCGA-KIRC |
| ENSG00000277443 | EPHA1-AS1,hsa-mir-216a,MARCKS | Male-specific ceRNA | TCGA-KIRC |
| ENSG00000277443 | SNHG5,hsa-mir-216a,MARCKS | Male-specific ceRNA | TCGA-KIRC |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7760922 | chr6:123116411:T:A | - | -0.0504019273499971 | 0.00733967016085356 | LUAD | Female-baised eQTL |
| rs11965179 | chr6:123118735:A:G | - | -0.0504019273499971 | 0.00733967016085356 | LUAD | Female-baised eQTL |
| rs62418666 | chr6:123119450:C:A | - | -0.0504019273499971 | 0.00733967016085356 | LUAD | Female-baised eQTL |
| rs4304189 | chr6:123111782:A:G | - | -0.0496937084385006 | 0.0131165257905764 | LUAD | Female-baised eQTL |
| rs7747399 | chr6:123112245:A:T | - | -0.0496937084385006 | 0.0131165257905764 | LUAD | Female-baised eQTL |
| rs62422183 | chr6:118564552:G:C | - | 0.091325039870064 | 0.0193041528705958 | LUAD | Female-baised eQTL |
| rs11153808 | chr6:119304889:C:T | - | 0.0427679792445593 | 0.0286661845500705 | LUAD | Female-baised eQTL |
| rs11759899 | chr6:119307951:A:C | - | 0.0427679792445593 | 0.0286661845500705 | LUAD | Female-baised eQTL |
| rs72966433 | chr6:119301915:T:C | - | 0.043007745849489 | 0.0286761261806198 | LUAD | Female-baised eQTL |
| rs10457352 | chr6:119302893:C:T | - | 0.0426093552380197 | 0.0319100366232819 | LUAD | Female-baised eQTL |
| rs6569070 | chr6:119301514:T:G | - | 0.041426670992181 | 0.0359575826829193 | LUAD | Female-baised eQTL |
| rs6923181 | chr6:119302970:A:T | - | 0.0389644606245781 | 0.0424471028036847 | LUAD | Female-baised eQTL |
| rs6934220 | chr6:119301070:T:G | - | 0.0405631904118715 | 0.0432090135420576 | LUAD | Female-baised eQTL |
| rs6911427 | chr6:119301076:C:T | - | 0.0405631904118715 | 0.0432090135420576 | LUAD | Female-baised eQTL |
| rs10872175 | chr6:119302388:T:C | - | 0.0400945978991413 | 0.0475159261224014 | LUAD | Female-baised eQTL |
| rs17686712 | chr6:123390908:G:C | - | 0.140688057041472 | 0.021161312617141 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12173906 | chr6:108149053:G:A | - | 0.201584831378199 | 0.0187611021858435 | SARC | Male-baised eQTL |
| rs1771756 | chr6:118697339:C:T | - | 0.0420289761845355 | 0.0355151362470711 | KIRC | Male-baised eQTL |
| rs11153351 | chr6:112257505:C:G | - | 0.0510664304624018 | 0.0408479199829445 | KIRC | Male-baised eQTL |
| rs12525583 | chr6:106601672:G:A | - | 0.103561479268929 | 0.000237209312322087 | COAD | Male-baised eQTL |
| rs6938201 | chr6:106608526:T:C | - | -0.113922953222131 | 0.00184119031659858 | COAD | Male-baised eQTL |
| rs339358 | chr6:116838847:T:C | - | 0.0744642317019593 | 0.00779051581998872 | COAD | Male-baised eQTL |
| rs339359 | chr6:116839530:G:A | - | 0.0744642317019593 | 0.00779051581998872 | COAD | Male-baised eQTL |
| rs339312 | chr6:116857525:A:G | - | 0.0732070581116745 | 0.00985294864207454 | COAD | Male-baised eQTL |
| rs88520 | chr6:116860503:C:A | - | 0.0732070581116745 | 0.00985294864207454 | COAD | Male-baised eQTL |
| rs339315 | chr6:116862444:T:C | - | 0.0729329703931989 | 0.00997417224052501 | COAD | Male-baised eQTL |
| rs339316 | chr6:116866015:T:C | - | 0.0729329703931989 | 0.00997417224052501 | COAD | Male-baised eQTL |
| rs339318 | chr6:116866747:G:A | - | 0.0729329703931989 | 0.00997417224052501 | COAD | Male-baised eQTL |
| rs339319 | chr6:116867572:C:T | - | 0.0729329703931989 | 0.00997417224052501 | COAD | Male-baised eQTL |
| rs339365 | chr6:116851055:A:G | - | 0.0730002995848957 | 0.0100309300251779 | COAD | Male-baised eQTL |
| rs143357 | chr6:116852414:C:T | - | 0.0730002995848957 | 0.0100309300251779 | COAD | Male-baised eQTL |
| rs339366 | chr6:116853428:C:T | - | 0.0730002995848957 | 0.0100309300251779 | COAD | Male-baised eQTL |
| rs339305 | chr6:116855594:A:C | - | 0.0730002995848957 | 0.0100309300251779 | COAD | Male-baised eQTL |
| rs339306 | chr6:116855811:A:C | - | 0.0730002995848957 | 0.0100309300251779 | COAD | Male-baised eQTL |
| rs339309 | chr6:116857166:T:C | - | 0.0730002995848957 | 0.0100309300251779 | COAD | Male-baised eQTL |
| rs339310 | chr6:116857220:T:G | - | 0.0730002995848957 | 0.0100309300251779 | COAD | Male-baised eQTL |
| rs339311 | chr6:116857238:A:C | - | 0.0730002995848957 | 0.0100309300251779 | COAD | Male-baised eQTL |
| rs339314 | chr6:116861515:C:T | - | 0.0730002995848957 | 0.0100309300251779 | COAD | Male-baised eQTL |
| rs339323 | chr6:116872349:G:A | - | 0.0726975385547087 | 0.0104660398752443 | COAD | Male-baised eQTL |
| rs339320 | chr6:116870086:G:A | - | 0.0724912042750281 | 0.0106622158023364 | COAD | Male-baised eQTL |
| rs339321 | chr6:116871027:G:A | - | 0.0724912042750281 | 0.0106622158023364 | COAD | Male-baised eQTL |
| rs761587 | chr6:110430923:T:C | - | -0.0711825436172411 | 0.0192487506534591 | COAD | Male-baised eQTL |
| rs733470 | chr6:110430909:C:G | - | -0.0689540705966318 | 0.0273767048539705 | COAD | Male-baised eQTL |
| rs761588 | chr6:110430833:A:G | - | -0.068829454639023 | 0.0281207288681852 | COAD | Male-baised eQTL |
| rs352068 | chr6:113940688:T:C | - | 0.090177131817668 | 0.0285144936489928 | COAD | Male-baised eQTL |
| rs352092 | chr6:113919521:T:C | - | -0.089235098755218 | 0.0305587875142822 | COAD | Male-baised eQTL |
| rs2820286 | chr6:104294670:G:T | - | 0.0688045853697509 | 0.0314062932888476 | COAD | Male-baised eQTL |
| rs12196845 | chr6:113942155:G:A | - | 0.0884496153026405 | 0.0330345861778795 | COAD | Male-baised eQTL |
| rs9385137 | chr6:120439984:G:A | - | 0.0624484195513919 | 0.0336993053699858 | COAD | Male-baised eQTL |
| rs4496833 | chr6:120440918:C:G | - | 0.0624484195513919 | 0.0336993053699858 | COAD | Male-baised eQTL |
| rs2357961 | chr6:120441040:A:T | - | 0.0624484195513919 | 0.0336993053699858 | COAD | Male-baised eQTL |
| rs10484457 | chr6:113465434:C:A | - | 0.0617043941557919 | 0.034231410866038 | COAD | Male-baised eQTL |
| rs2357962 | chr6:120441058:A:G | - | 0.0611236290144326 | 0.0344228809982852 | COAD | Male-baised eQTL |
| rs10872203 | chr6:120441698:A:C | - | 0.0611236290144326 | 0.0344228809982852 | COAD | Male-baised eQTL |
| rs746002 | chr6:110430388:T:C | - | -0.0672699504881173 | 0.0344894966412487 | COAD | Male-baised eQTL |
| rs11153462 | chr6:114081175:T:C | - | 0.0635475264110596 | 0.0348524101035733 | COAD | Male-baised eQTL |
| rs1843597 | chr6:120444126:G:A | - | 0.060520473759804 | 0.0361319378010577 | COAD | Male-baised eQTL |
| rs1619049 | chr6:118719563:T:C | - | -0.104092098063753 | 0.036557986960924 | COAD | Male-baised eQTL |
| rs28558559 | chr6:113863071:T:C | gene,exon,UTR | 0.088875797970846 | 0.0371143779562483 | COAD | Male-baised eQTL |
| rs9487404 | chr6:110429276:T:C | - | -0.0649581751659217 | 0.0374324412552046 | COAD | Male-baised eQTL |
| rs742939 | chr6:110430318:T:C | - | -0.0664214961069245 | 0.0381535300385253 | COAD | Male-baised eQTL |
| rs742938 | chr6:110430379:A:C | - | -0.0664214961069245 | 0.0381535300385253 | COAD | Male-baised eQTL |
| rs559295 | chr6:104303613:C:T | - | 0.0647150376400254 | 0.0398939929332475 | COAD | Male-baised eQTL |
| rs2604500 | chr6:104302443:A:G | - | 0.0640154809161455 | 0.0443395984824388 | COAD | Male-baised eQTL |
| rs1149311 | chr6:105302535:T:C | - | -0.117443776717199 | 0.0446557981793961 | COAD | Male-baised eQTL |
| rs339334 | chr6:116891526:A:G | - | 0.0655086549477633 | 0.0447493744157528 | COAD | Male-baised eQTL |
| rs434499 | chr6:116892451:T:C | - | 0.0655086549477633 | 0.0447493744157528 | COAD | Male-baised eQTL |
| rs339340 | chr6:116893951:T:C | - | 0.0655086549477633 | 0.0447493744157528 | COAD | Male-baised eQTL |
| rs339341 | chr6:116894508:A:G | - | 0.0655086549477633 | 0.0447493744157528 | COAD | Male-baised eQTL |
| rs1149308 | chr6:105301083:T:G | - | -0.111788624739655 | 0.044775573767243 | COAD | Male-baised eQTL |
| rs610424 | chr6:116891095:T:C | - | 0.0655364532045659 | 0.0449143783090473 | COAD | Male-baised eQTL |
| rs9372256 | chr6:110428459:A:G | - | -0.0629887959576741 | 0.045326098862804 | COAD | Male-baised eQTL |
| rs2295189 | chr6:110428550:T:C | - | -0.0629887959576741 | 0.045326098862804 | COAD | Male-baised eQTL |
| rs2295187 | chr6:110428844:T:C | - | -0.0629887959576741 | 0.045326098862804 | COAD | Male-baised eQTL |
| rs1564971 | chr6:120442909:G:A | - | 0.0589494579181535 | 0.0497188940473002 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000277443 |
| CpG Site: cg10474881 | |
| Position to Gene: gene,exon,enhancer,CDS | |
| Male Effect: - | |
| Female Effect: -0.203820704204853 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg10474881 | chr6:113860510 | gene,exon,enhancer,CDS | -0.203820704204853 | 4.38024225471154e-06 | -0.34612092147198475 | 1.3758137117105242e-08 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of MARCKS |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000277443 | MARCKS | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
| ENSG00000277443 | MARCKS | C0010606 | Adenoid Cystic Carcinoma | 1 | CTD_human |
| ENSG00000277443 | MARCKS | C0024121 | Lung Neoplasms | 1 | CTD_human |
| ENSG00000277443 | MARCKS | C0036095 | Salivary Gland Neoplasms | 1 | CTD_human |
| ENSG00000277443 | MARCKS | C0220636 | Malignant neoplasm of salivary gland | 1 | CTD_human |
| ENSG00000277443 | MARCKS | C0242379 | Malignant neoplasm of lung | 1 | CTD_human |
